Contact this trialFirst, we need to learn more about you.
Chemotherapy
Entrectinib +1 More for Uveal Melanoma
Recruiting1 awardPhase 1 & 2
Minneapolis, Minnesota
This trial tests PAC-1 and Entrectinib, which are oral medications. PAC-1 is taken over a few weeks, and Entrectinib is taken daily. The trial targets patients with diseases like cancer. PAC-1 kills cancer cells, and Entrectinib stops them from growing. Paclitaxel (PAC) is one of the major anti-cancer drugs, effective in different tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.